Artwork

内容由America's Healthcare Advocate and Cary Hall提供。所有播客内容(包括剧集、图形和播客描述)均由 America's Healthcare Advocate and Cary Hall 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Brisk Walking or $13k Per Year for Weight Loss Drug - We Review Options, Cost, Ozempic & Wecovy

33:52
 
分享
 

Manage episode 414772659 series 1279924
内容由America's Healthcare Advocate and Cary Hall提供。所有播客内容(包括剧集、图形和播客描述)均由 America's Healthcare Advocate and Cary Hall 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Whether you are wanting to lose weight, prevent Type 2 Diabetes or both, you now can consider the class of drugs described as "glucagon-like peptide-1 (GLP-1) agonists" that work by binding to GLP-1 receptors, which in turn results in lower blood sugar levels and A1C levels and are now being prescribed to reduce appetite and help with weight loss. But there is a high financial cost and you may need to stay on the drug for life. In this episode, I will discuss the latest on Ozempic and Wegovy and which is approved by the US Food and Drug Administration to treat diabetes and which to help with weight loss or to lower risk of cardiovascular disease. Then we contrast these drugs with the latest knowledge about the effectiveness of "Brisk Walking" as I bring you the latest health and well-being news in this Multi-Topic episode! I'm Cary Hall, America's Healthcare Advocate. Ep 2011 Need help or have something to share? https://www.americashealthcareadvocate.com/contact-us
  continue reading

352集单集

Artwork
icon分享
 
Manage episode 414772659 series 1279924
内容由America's Healthcare Advocate and Cary Hall提供。所有播客内容(包括剧集、图形和播客描述)均由 America's Healthcare Advocate and Cary Hall 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Whether you are wanting to lose weight, prevent Type 2 Diabetes or both, you now can consider the class of drugs described as "glucagon-like peptide-1 (GLP-1) agonists" that work by binding to GLP-1 receptors, which in turn results in lower blood sugar levels and A1C levels and are now being prescribed to reduce appetite and help with weight loss. But there is a high financial cost and you may need to stay on the drug for life. In this episode, I will discuss the latest on Ozempic and Wegovy and which is approved by the US Food and Drug Administration to treat diabetes and which to help with weight loss or to lower risk of cardiovascular disease. Then we contrast these drugs with the latest knowledge about the effectiveness of "Brisk Walking" as I bring you the latest health and well-being news in this Multi-Topic episode! I'm Cary Hall, America's Healthcare Advocate. Ep 2011 Need help or have something to share? https://www.americashealthcareadvocate.com/contact-us
  continue reading

352集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南